BEIGF:OTCMKTS
BeOne Medicines
US$ 21.95
0.00%
(0.00) Siku 1
9 Jun, 12:49:46 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya BEIGF...
Mtaji wa soko
42.40B
Wastani wa kiasi cha mauzo
0.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$ 24.92
Chini kwa wiki 52
US$ 21.95
Beta
0.84
Hisa za wawekezaji
1.43B
Idadi ya wafanyakazi
elfu 12
Mtaji wa soko
42.40B
Wastani wa kiasi cha mauzo
0.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$ 24.92
Chini kwa wiki 52
US$ 21.95
Beta
0.84
Hisa za wawekezaji
1.43B
Idadi ya wafanyakazi
elfu 12
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Simply Wall Street
·
dakika 2 zilizopita
After AbCellera Biologics' 125% Climb, The Story Has Changed
CoinDesk
·
saa 2 zilizopita
Bitcoin rebounds above $83,000 as it decouples from tumbling Korean stocks and Nasdaq futures
Carroll County Mirror-Democrat
·
dakika 45 zilizopita
Abishai Financial Asia Reports S&P 500 Tech-Led Advance
Yahoo Finance
·
dakika 47 zilizopita
Stock Market: Will S&P 500 Open Up or Down Today?
Wasifu
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Kuhusu BeOne Medicines
Afisa Mkuu Mtendaji (CEO)John Vincent Oyler | John Vincent Oyler
Wafanyakazielfu 12
Lilianzishwa28 Okt 2010
Makao makuu-
Sekta-
Tovutibeonemedicines.com